Kiora Pharmaceuticals (KPRX) Non Operating Income (2014 - 2026)

Kiora Pharmaceuticals (KPRX) has reported Non Operating Income for 13 consecutive years, with $134761.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non Operating Income rose 2.34% year-over-year to $134761.0; the trailing twelve-month figure through Jun 2026 stood at $548682.0 (down 44.42% YoY), and the FY2025 full-year result was $713770.0, down 37.9% from the prior year.
• Non Operating Income advanced to $134761.0 in Q2 2026 per KPRX's latest filing, from $92212.0 in the prior quarter.
• Across five years, Non Operating Income topped out at $406185.0 in Q4 2024 and bottomed at -$1.4 million in Q3 2022.
• Historically, Non Operating Income has averaged $48134.1 across 5 years, with a median of $133220.5 in 2025.
• The sharpest annual moves came in 2022 and 2024: Non Operating Income tumbled 546935.52% in 2022, then surged 1583.63% in 2024.
• Over 5 years, Non Operating Income stood at $23542.0 in 2022, then slumped by 353.33% to -$59638.0 in 2023, then surged by 781.08% to $406185.0 in 2024, then tumbled by 64.65% to $143595.0 in 2025, then retreated by 6.15% to $134761.0 in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered $134761.0, $92212.0, and $143595.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.